Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27585110 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL32685326 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL19223918 | 0.84 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL12251031 | 0.82 | CYP19A1 (0.54) | CHRNB2P4HTMCHRNA3 | |
| SCHEMBL12667879 | 0.81 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL29656789 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL6750074 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL16115213 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL29583143 | 0.78 | — | — | |
| SCHEMBL434891 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021222308-A1 | SSAO INHIBITORS FOR THE TREATMENT OF DISEASE | METACRINE, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20190295778-A1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF | FUJIFILM CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
| US-9957238-B2 | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, PNLIP | CHRNB2 4366/4885CHRNA4 4115/4885P4HTM 887/4885 |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | CHRNB2 3877/4885CHRNA4 4413/4885P4HTM 830/4885 |
| US-20190295778-A1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF | LEF1, MLLT3, CRY1 | CHRNB2 2936/4885CHRNA4 992/4885P4HTM 1439/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | CHRNB2 4040/4885CHRNA4 4546/4885P4HTM 628/4885 |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | CHRNB2 376/4885CHRNA4 648/4885P4HTM 1052/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | CHRNB2 2526/4885CHRNA4 3695/4885P4HTM 4344/4885 |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | CHRNB2 4524/4885CHRNA4 4398/4885P4HTM 1379/4885 |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | CHRNB2 3877/4885CHRNA4 4413/4885P4HTM 830/4885 |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | CHRNB2 212/4885CHRNA4 391/4885P4HTM 1034/4885 |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | CHRNB2 3226/4885CHRNA4 3870/4885P4HTM 1210/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | CHRNB2 212/4885CHRNA4 391/4885P4HTM 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.